Short title: Therapy-related MDS and AML after radioiodine treatment
暂无分享,去创建一个
R. Schlenk | N. Kröger | I. Bruns | U. Germing | G. Kobbe | R. Fenk | R. Haas | A. Czibere | U. Platzbecker | N. Gattermann | M. Stadler | D. Haase | A. Kuendgen | T. Schroeder | S. Kayser | F. Zohren | F. Braulke | Viola Klärner
[1] Verena I Gaidzik,et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] K. Döhner,et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. , 2011, Blood.
[3] A. Wölfler,et al. Therapy‐related myeloid neoplasms: pathobiology and clinical characteristics , 2011, British journal of pharmacology.
[4] D. Preston,et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Larson,et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. , 2010, Chemico-biological interactions.
[6] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[7] S. Acharya,et al. Current and emerging treatment options for Graves’ hyperthyroidism , 2009, Therapeutics and clinical risk management.
[8] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[9] S. Straus,et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. , 2009, Thyroid : official journal of the American Thyroid Association.
[10] N. Kröger,et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation , 2009, Haematologica.
[11] A. Hagemeijer,et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Larson,et al. Therapy-related myeloid leukemia. , 2008, Seminars in oncology.
[13] Rainer Haas,et al. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes , 2008, Annals of Hematology.
[14] Rebeccah L. Brown. Standard and emerging therapeutic approaches for thyroid malignancies. , 2008, Seminars in oncology.
[15] F. Vathaire. The carcinogenic effects of radioiodine therapy for thyroid carcinoma , 2008, Nature Clinical Practice Endocrinology &Metabolism.
[16] Thomas H Müller,et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.
[17] U. Germing,et al. Prognostic Factors in Treatment-Related Myelodysplastic Syndromes (t-MDS) and Acute Myeloid Leukemia (t-AML). , 2007 .
[18] B. Ko,et al. RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome , 2007, British journal of haematology.
[19] M. Voso,et al. Therapy-related leukemia and myelodysplasia: susceptibility and incidence , 2007, Haematologica.
[20] D. Focosi,et al. Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases , 2007, Haematologica.
[21] T. Haferlach,et al. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. , 2007, Haematologica.
[22] J. Grudeva-Popova,et al. Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review. , 2007, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.
[23] D. Christiansen,et al. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia , 2005, Leukemia.
[24] J. Shay,et al. Lack of mutations of the human telomerase RNA gene (hTERC) in myelodysplastic syndrome. , 2005, Haematologica.
[25] P. Macpherson,et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. , 2004, Blood.
[26] W. Hiddemann,et al. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML , 2004, Leukemia.
[27] Sonali M. Smith,et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. , 2003, Blood.
[28] P. Hall,et al. Late consequences of radioiodine for diagnosis and therapy in Sweden. , 1997, Thyroid : official journal of the American Thyroid Association.
[29] E. Estey,et al. Treatment of therapy-related leukemia and myelodysplastic syndrome. , 1993, Hematology/oncology clinics of North America.
[30] C. Edmonds,et al. The long-term hazards of the treatment of thyroid cancer with radioiodine. , 1986, The British journal of radiology.
[31] J. Fraumeni,et al. Cancer incidence following treatment of hyperthyroidism. , 1982, International journal of epidemiology.